[go: up one dir, main page]

WO2009043987A9 - Antibiotic compositions containing essential oils, prophylaxis and treatment of nosocomial diseases - Google Patents

Antibiotic compositions containing essential oils, prophylaxis and treatment of nosocomial diseases Download PDF

Info

Publication number
WO2009043987A9
WO2009043987A9 PCT/FR2008/001012 FR2008001012W WO2009043987A9 WO 2009043987 A9 WO2009043987 A9 WO 2009043987A9 FR 2008001012 W FR2008001012 W FR 2008001012W WO 2009043987 A9 WO2009043987 A9 WO 2009043987A9
Authority
WO
WIPO (PCT)
Prior art keywords
prophylaxis
treatment
containing essential
compositions containing
essential oils
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/FR2008/001012
Other languages
French (fr)
Other versions
WO2009043987A1 (en
Inventor
Elisabeth Marie-Ange Yvette Rossines
Gérard Panhelleux
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aroma Technologies SAS
Original Assignee
Aroma Technologies SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aroma Technologies SAS filed Critical Aroma Technologies SAS
Priority to EP08834729A priority Critical patent/EP2175870A1/en
Publication of WO2009043987A1 publication Critical patent/WO2009043987A1/en
Publication of WO2009043987A9 publication Critical patent/WO2009043987A9/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The invention set forth in the present application relates to a novel antibiotic composition, to novel drug associations and novel formulations containing essential oil(s), as well as to the use thereof for the prophylaxis and/or treatment of infections in general and of nosocomial bacterial infections in particular. The invention also relates to a method for reducing the amount of bacteria present on a surface. The invention also relates to a method for preventing or treating a bacterial infection, in particular a nosocomial infection, in a mammal and particularly a human being, said method comprising (i) the administration of at least one antibiotic and (ii) the administration of at least one essential oil(s) formulation. The compounds (i) and (ii) can be administered simultaneously (in the form of a mixture or alternatively in the form of separate formulations) and/or separately.
PCT/FR2008/001012 2007-07-10 2008-07-10 Antibiotic compositions containing essential oils, prophylaxis and treatment of nosocomial diseases Ceased WO2009043987A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP08834729A EP2175870A1 (en) 2007-07-10 2008-07-10 Antibiotic compositions containing essential oils, prophylaxis and treatment of nosocomial diseases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0704991 2007-07-10
FR0704991A FR2918571B1 (en) 2007-07-10 2007-07-10 ANTIBIOTIC COMPOSITIONS BASED ON ESSENTIAL OILS PROPHYLAXIS AND TREATMENT OF NOSOCOMIAL INFECTIONS

Publications (2)

Publication Number Publication Date
WO2009043987A1 WO2009043987A1 (en) 2009-04-09
WO2009043987A9 true WO2009043987A9 (en) 2009-10-01

Family

ID=39135270

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2008/001012 Ceased WO2009043987A1 (en) 2007-07-10 2008-07-10 Antibiotic compositions containing essential oils, prophylaxis and treatment of nosocomial diseases

Country Status (3)

Country Link
EP (1) EP2175870A1 (en)
FR (1) FR2918571B1 (en)
WO (1) WO2009043987A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2946255B1 (en) * 2009-06-05 2013-05-24 Natepharm COMPOSITION COMPRISING TRANS-CINNAMALDEHYDE
IT1401202B1 (en) * 2010-07-26 2013-07-12 Ist Superiore Sanita USE OF TERPINEN-4-OL AS AN ANTIMICROBIAL AGENT AGAINST LEGIONELLA PNEUMOPHILA.
US9492398B2 (en) 2011-02-25 2016-11-15 Eydo Pharma Nanocapsulation of essential oils for preventing or curing infectious diseases alone or with an antibiotic
FR3021218A1 (en) * 2014-05-26 2015-11-27 Eydo Pharma USE OF CINNAMALDEHYDE IN COMBINATION WITH EUGENOL AND / OR CARVACROL TO COMBAT ANTIBIOTIC RESISTANCE
FR3048612B1 (en) 2016-03-14 2020-10-02 Septeos POTENTIALIZED TULATHROMYCIN
GB201904963D0 (en) * 2019-04-08 2019-05-22 Anpario Plc Composition for reducing antimicrobial resistance
US12460153B2 (en) 2019-12-04 2025-11-04 Pranarom International S.A. Method for transforming an essential oil
EP4262839A1 (en) * 2020-10-16 2023-10-25 Herbelixa Doo Sremska Kamenica Herbal preparation for prevention and treatment of helicobacter pylori infection
CN112618486B (en) * 2020-12-24 2023-07-18 浙江昂利康制药股份有限公司 Suspension oil for injection and preparation method thereof
FR3120187B1 (en) * 2021-02-26 2023-12-01 Mathieu Angelidis Natural repellent composition
CN113633614B (en) * 2021-09-08 2023-04-07 中国人民解放军陆军军医大学 Efficient antibacterial natural tea tree essential oil nanoemulsion preparation for treating intractable dental ulcer and preparation method and application thereof
CN113767937A (en) * 2021-09-10 2021-12-10 江西中医药大学 Compound essential oil composition, preparation method and application

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1146111A1 (en) * 2000-04-14 2001-10-17 The Procter & Gamble Company Process of disinfecting a hard-surface with a composition comprising cinnamon oil and/or an active thereof
US6884763B2 (en) * 2001-10-30 2005-04-26 Permatex, Inc. Waterless hand cleaner containing plant derived natural essential oil
US20040071757A1 (en) * 2001-11-20 2004-04-15 David Rolf Inhalation antiviral patch
AU2003282358A1 (en) * 2002-11-21 2004-06-15 J.P.M.E.D. Ltd. Compositions for treating infected skin and mucous membrane comprising an anti-microbial agent and an essential oil
GB0405545D0 (en) * 2004-03-12 2004-04-21 Univ Manchester Antimicrobial composition
WO2006120494A1 (en) * 2005-05-13 2006-11-16 Advanced Scientific Developements Pharmaceutical combination comprising an antibacterial agent and an active substance selected from carveol, thymol, eugenol, borneol and carvacrol

Also Published As

Publication number Publication date
FR2918571B1 (en) 2013-01-11
FR2918571A1 (en) 2009-01-16
EP2175870A1 (en) 2010-04-21
WO2009043987A1 (en) 2009-04-09

Similar Documents

Publication Publication Date Title
WO2009043987A9 (en) Antibiotic compositions containing essential oils, prophylaxis and treatment of nosocomial diseases
WO2008092006A3 (en) Antimicrobial compositions
BRPI1007379B8 (en) pharmaceutical compositions for the treatment or prevention of oral infections by e. coli
AU2003241345A1 (en) Use of mastic and its components for the control of microbial infections
NZ701559A (en) Compositions comprising povidone-iodine
NO20092542L (en) Antibacterial quinoline derivatives
TWI327573B (en) 6-11 bicyclic ketolide derivatives
EA033311B1 (en) Benzoxaborole derivatives as antibacterial agents
BR112015014458A2 (en) mannose derivatives for the treatment of bacterial infections
MY143795A (en) Tetrahydropyridoindole derivatives
WO2008071961A8 (en) 2-quinolinone and 2-quinoxalinone- derivatives and their use as antibacterial agents
WO2009019708A3 (en) Pharmaceutical compositions and methods for the treatment of cancer
NO20092547L (en) Antibacterial quinoline derivatives
WO2006063039A3 (en) 3, 6-bicyclolides
WO2006039263A3 (en) NOVEL BICYCLIC 9a-AZALIDE DERIVATIVES
NO20092536L (en) Antibacterial quinoline derivatives
NO20092540L (en) Antibacterial quinoline derivatives
WO2005067564A3 (en) 6-11 bicyclic erythromycin derivatives
NO20092541L (en) Antibacterial quinoline derivatives
WO2006065721A3 (en) 11, 12-lactone bicyclolides
WO2009124086A3 (en) Antibacterial drug for treatment of staphylococcus aureus and other gram-positive bacterial infections
WO2008014221A3 (en) Bridged carbamate macrolides
BR112023019720A2 (en) USE OF RIFAMICIN ANALOGUES IN COMBINATION WITH VANCOMICIN, PHARMACEUTICAL COMPOSITION COMPRISING THESE COMPOUNDS, IN VITRO METHOD FOR PREVENTING OR INHIBITING THE GROWTH OF A BACTERIA AND KIT
TW200635600A (en) Tetracyclic bicyclolides
WO2010086617A3 (en) Phosphoantigens for the treatment of burkholderia infections

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08834729

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2008834729

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2008834729

Country of ref document: EP